Upfront Briefing
Cytokinetics reads out ACACIA-HCM topline this morning (8am ET) — the first Phase 3 test of aficamten in non-obstructive HCM and one of the year's biggest cardiovascular biotech catalysts. Vertex meanwhile discontinued Moderna-partnered VX-522, ending a high-upside CF franchise extension over persistent inhaled-LNP tolerability.
On the capital side, BioMarin closed Amicus and raised FY26 revenue guidance to $3.825–3.925B (+20% Y/Y); Abivax priced a $45M ADS deal alongside a royalty-certificate buyback; J&J's DUET combo missed in IBD — a quiet positive read-through for Abivax. Biotech beta caught a bid (XBI +2.4%, NBI +1.7%) while the broader tape sold off on Iran headlines and rising oil.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,200.8 |
(0.4%) |
+4.1% |
| Nasdaq 100 |
27,651.8 |
(0.2%) |
+9.1% |
| Russell 2000 |
2,796.0 |
(0.6%) |
+5.6% |
| Healthcare (XLV) |
144.7 |
(0.3%) |
(5.7%) |
| Biotech (XBI) |
133.5 |
+2.4% |
+4.6% |
| Nasdaq Biotech (NBI) |
5,899.9 |
+1.7% |
(0.2%) |
| Clinical Trials (BBC) |
44.8 |
+2.3% |
+6.2% |
|
- Risk-off broader tape (Dow (1.1%), S&P 500 (0.4%)) on Iran/UAE missile headlines and oil +4.4% to $106 — energy was the only S&P sector higher.
- Biotech decoupled hard: XBI +2.4%, NBI +1.7%, BBC +2.3% — the UCB/Candid premium ($2B upfront for a mostly Phase 1 TCE platform) re-rated autoimmune comps, while Odyssey IPO terms and Abivax's $45M ADS deal added to the active capital tape.
- Healthcare lagged biotech (XLV (0.3%)) — split between defensive large-cap pharma/managed-care and higher-beta innovation, a familiar pattern when M&A and IPO supply do the heavy lifting.
- Market data: U.S. close Mon 04-May-2026.
The Big 3
|
1
|
Cytokinetics reads out ACACIA-HCM today — aficamten's biggest test
|
- Cytokinetics will report topline data this morning (8am ET) from ACACIA-HCM, the pivotal Phase 3 of aficamten (MYQORZO) in ~500 patients with non-obstructive hypertrophic cardiomyopathy. Dual primary endpoints: change in KCCQ Clinical Summary Score and peak VO2 at Week 36.
- Why it matters: Aficamten is already approved in obstructive HCM (US/EU/China) and BMY's Camzyos is the de facto comp; nHCM roughly doubles the addressable population (~half of HCM is non-obstructive) and is currently a label-free market. A clean win on both endpoints opens Cytokinetics' path to a sNDA and a step-up in the consensus peak sales build for aficamten; a miss on peak VO2 (a high bar in a heterogeneous population) would compress the franchise narrative back to oHCM and add pressure to a name that has already been a 2026 outperformer. Watch read-through to Edgewise (EWTX) and BMY/Camzyos.
- Source: PR
|
|
2
|
Abivax cleans the cap table; J&J DUET miss is a quiet tailwind
|
- Abivax priced a $45M (€38.5M) ADS offering alongside a repurchase of legacy royalty certificates — equity-funded simplification that protects future obefazimod economics. Runway extended into Q4 2027; obefazimod Phase 3 maintenance UC data due H2 2026.
- Why it matters: The trade is short-term dilution (~3% on a ~€1.4B market cap) for a cleaner long-term claim on obefazimod cash flows — a structural positive ahead of any take-out conversation (Truist's "take-out darling" thesis still live). The same morning, J&J's DUET-UC/DUET-Crohn's combo missed primary endpoint of clinical remission in 2L+ IBD, partially de-risking Abivax's competitive position in the increasingly crowded oral UC market and pushing combination-therapy timelines for the largest competitor back. Net: cleaner cap table + competitor stumble = better optionality into the H2 readout.
- Source: PR / STAT (J&J read-through)
|
|
3
|
Vertex kills VX-522 — second inhaled mRNA-LNP failure for CF
|
- Disclosed on Q1 2026 earnings call: Vertex discontinued VX-522 (Moderna-partnered, mRNA-3692) over persistent lung inflammation tied to the LNP delivery vehicle. The Phase 1/2 had been on a tolerability pause since May 2025 and the company can no longer assess efficacy. VRTX (0.8%) AH to $426.58 (–5.2% YTD); Q1 revenue $2.99B (+8% Y/Y), FY guide reiterated.
- Why it matters: VX-522 was the centerpiece of Vertex's strategy to reach the ~10% of CF patients ineligible for CFTR modulators — the only meaningful franchise-extension lever in CF beyond Alyftrek/Trikafta line extensions. Removal closes the modality option Vertex paid Moderna $75M to access in 2020. More broadly, this is the second inhaled mRNA-LNP failure in CF (Arcturus showed lack of efficacy in October 2025), reinforcing that pulmonary delivery remains the bottleneck for the modality — a negative read-through for Moderna's inhaled program (which had no other candidates) and for any biotech assuming inhaled-LNP is solved. Vertex's near-term revenue base remains intact; the long-term franchise diversification story now leans harder on povetacicept (renal), Casgevy and Journavx.
- Source: Fierce Biotech / Endpoints
|
Everything Else that broke
- BioMarin closed Amicus and raised FY26 revenue guide to $3.825–3.925B (~20% Y/Y); Q1 product sales benefited from VOXZOGO patient growth +20% Y/Y. — PR
- Pfizer reports Q1 2026 this morning (consensus ~$13.82B revenue / ~$0.74 EPS); guidance update + ELREXFIO Phase 3 commentary in focus. — PFE IR
- J&J's DUET combination (Tremfya + Simponi / JNJ-4804) failed primary endpoint of clinical remission in two Phase 2b IBD trials; J&J still plans to advance into Phase 3 in a subgroup. — STAT
- Mirum's Phase 2b VISTAS hit primary endpoint — volixibat delivered statistically significant reductions in cholestatic pruritus (vs placebo) in 111 PSC patients with moderate-to-severe itch; supports a potential first-to-market itch claim in PSC. — PR
- Takeda's TAK-881 (SCIG 20% + hyaluronidase) showed PK comparability to HYQVIA in pivotal Phase 2/3 in PID with reduced infusion volume and time; US/EU/Japan filings expected in FY2026 — a HYQVIA franchise extension play, not novel MoA. — PR
- UCB to acquire Candid Therapeutics for up to $2.2B ($2B upfront + $200M milestones), pre-empting a planned Rallybio reverse merger and $505M crossover (covered Monday). — UCB PR
- Celcuity strengthened the ASCO case for gedatolisib in HR+/HER2– breast cancer ahead of the 31-May Plenary. — BioPharma Dive
- CRISPR Therapeutics and Nuvation Bio reported Q1 2026 results and provided business updates. — CRSP PR / NUVB PR
- Aktis initiated Phase 1b of AKY-2519 (B7-H3 radioconjugate) in mCRPC; Cellenkos cleared IND for CK0802 in steroid-refractory GVHD; Nanobiotix announced an FDA-accepted protocol amendment for its global Phase 3 head and neck study. — Aktis / Cellenkos / Nanobiotix
- A sertraline manufacturer recalled a batch after a UK packaging mix-up. — BioSpace
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- No new transactions announced since yesterday.
VC / Private Financings
- Latus Bio closed a $97M Series A for scalable AAV gene therapies (incl. a $43M extension led by 8VC). Existing investors DCVC Bio, BioAdvance, Benjamin Franklin Technology Partners, Modi Ventures, Gaingels and Hatch BioFund participated; new investors Korea Development Bank and Helen's Pink Sky Foundation joined. Lead programs: LTS-201 (Huntington's, IND Q3 2026) and LTS-101 (CLN2, POC Q4 2026). — PR
IPOs / Follow-Ons
- Odyssey Therapeutics (autoimmune/inflammatory; lead RIPK2 inhibitor in Phase 2 UC) set terms for its Nasdaq IPO at $16–$18 per share, 13.2M shares, raising up to $238.3M at up to ~$810M market cap. Trades as ODTX; pricing expected this week. JPM, TD Cowen and Cantor lead. — Reuters
|
